BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 17164294)

  • 21. Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.
    Regmi A; Fuson T; Yang X; Kays J; Moxham C; Zartler E; Chandrashekhar S; Galvin RJ
    Bone; 2005 Feb; 36(2):284-91. PubMed ID: 15780954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
    Balga R; Wetterwald A; Portenier J; Dolder S; Mueller C; Hofstetter W
    Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The mechanism of osteoclast differentiation induced by IL-1.
    Kim JH; Jin HM; Kim K; Song I; Youn BU; Matsuo K; Kim N
    J Immunol; 2009 Aug; 183(3):1862-70. PubMed ID: 19587010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The molecular understanding of osteoclast differentiation.
    Asagiri M; Takayanagi H
    Bone; 2007 Feb; 40(2):251-64. PubMed ID: 17098490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitory effect of (-)-saucerneol on osteoclast differentiation and bone pit formation.
    Kim SN; Kim MH; Kim YS; Ryu SY; Min YK; Kim SH
    Phytother Res; 2009 Feb; 23(2):185-91. PubMed ID: 18690659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
    Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
    Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis.
    Koga T; Inui M; Inoue K; Kim S; Suematsu A; Kobayashi E; Iwata T; Ohnishi H; Matozaki T; Kodama T; Taniguchi T; Takayanagi H; Takai T
    Nature; 2004 Apr; 428(6984):758-63. PubMed ID: 15085135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
    Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
    Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RANKL-stimulated TNFalpha production in osteoclast precursor cells promotes osteoclastogenesis by modulating RANK signaling pathways.
    Nakao A; Fukushima H; Kajiya H; Ozeki S; Okabe K
    Biochem Biophys Res Commun; 2007 Jun; 357(4):945-50. PubMed ID: 17467668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF.
    Knowles HJ; Athanasou NA
    J Pathol; 2008 May; 215(1):56-66. PubMed ID: 18283716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways.
    Park JY; Bae MA; Cheon HG; Kim SS; Hong JM; Kim TH; Choi JY; Kim SH; Lim J; Choi CH; Shin HI; Kim SY; Park EK
    Biochem Biophys Res Commun; 2009 Jan; 378(3):645-9. PubMed ID: 19059209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Attenuation of osteoclastogenesis and osteoclast function by apigenin.
    Bandyopadhyay S; Lion JM; Mentaverri R; Ricupero DA; Kamel S; Romero JR; Chattopadhyay N
    Biochem Pharmacol; 2006 Jul; 72(2):184-97. PubMed ID: 16750176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Caffeic acid phenethyl ester inhibits osteoclastogenesis by suppressing NF kappaB and downregulating NFATc1 and c-Fos.
    Ha J; Choi HS; Lee Y; Lee ZH; Kim HH
    Int Immunopharmacol; 2009 Jun; 9(6):774-80. PubMed ID: 19285574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Osteoclast culture and resorption assays.
    Bradley EW; Oursler MJ
    Methods Mol Biol; 2008; 455():19-35. PubMed ID: 18463808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Receptor activator of nuclear factor-kappa B ligand induces osteoclast formation in RAW 264.7 macrophage cells via augmented production of macrophage-colony-stimulating factor.
    Islam S; Hassan F; Tumurkhuu G; Dagvadorj J; Koide N; Naiki Y; Yoshida T; Yokochi T
    Microbiol Immunol; 2008 Dec; 52(12):585-90. PubMed ID: 19120972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts.
    Komano Y; Nanki T; Hayashida K; Taniguchi K; Miyasaka N
    Arthritis Res Ther; 2006; 8(5):R152. PubMed ID: 16987426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts.
    Kindle L; Rothe L; Kriss M; Osdoby P; Collin-Osdoby P
    J Bone Miner Res; 2006 Feb; 21(2):193-206. PubMed ID: 16418775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Momordin I, an inhibitor of AP-1, suppressed osteoclastogenesis through inhibition of NF-kappaB and AP-1 and also reduced osteoclast activity and survival.
    Hwang YH; Lee JW; Hahm ER; Jung KC; Lee JH; Park CH; Rhee HS; Ryu JM; Kim HK; Yang CH
    Biochem Biophys Res Commun; 2005 Nov; 337(3):815-23. PubMed ID: 16213465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psoralen and Bakuchiol Ameliorate M-CSF Plus RANKL-Induced Osteoclast Differentiation and Bone Resorption Via Inhibition of AKT and AP-1 Pathways in Vitro.
    Chai L; Zhou K; Wang S; Zhang H; Fan N; Li J; Tan X; Hu L; Fan X
    Cell Physiol Biochem; 2018; 48(5):2123-2133. PubMed ID: 30110702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; RĂ©dini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.